EPT0776
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- e1_e2
- E1
- umap1_2d
- -2.837464996
- umap2_2d
- 2.928760985
- umap1_3d
- 0.562685277
- umap2_3d
- 0.077368535
- umap3_3d
- -1.926029311
- dataset
- EPN-Toronto
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.360
- PANCREAS_BETA_CELLS+0.240
- IL6_JAK_STAT3_SIGNALING+0.230
- ALLOGRAFT_REJECTION+0.220
- INFLAMMATORY_RESPONSE+0.200
- APICAL_SURFACE+0.190
- SPERMATOGENESIS+0.190
- COAGULATION+0.120
- INTERFERON_GAMMA_RESPONSE+0.050
- COMPLEMENT+0.000
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.520
- ADIPOGENESIS-0.470
- CHOLESTEROL_HOMEOSTASIS-0.450
- WNT_BETA_CATENIN_SIGNALING-0.440
- NOTCH_SIGNALING-0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- MYC_TARGETS_V1-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.390
- DNA_REPAIR-0.380
- UV_RESPONSE_UP-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8942994 | — | — | 0.935 |
| 2 | SRR662342 | GTEX | — | 0.911 |
| 3 | MNG1126 | — | — | 0.907 |
| 4 | SRR1413454 | GTEX | — | 0.902 |
| 5 | MNG1137 | — | — | 0.898 |
| 6 | SRR598533 | GTEX | — | 0.898 |
| 7 | SRR934910 | — | — | 0.897 |
| 8 | SRR1435884 | GTEX | — | 0.892 |
| 9 | MDT-AP-1143 | Med | Medulloblastoma | 0.891 |
| 10 | MNG1142 | — | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.050 | Idelalisib | — uncovered |